Depression trials recruiting in Connecticut

All Depression trials nationally

Cities in Connecticut

Recruiting trials in Connecticut

• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Connecticut: Cromwell
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
  NCT07076407 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Connecticut: Hartford
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Connecticut: New Haven
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
  NCT06793397 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Connecticut: New Haven
• A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
  NCT07065240 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Connecticut: Cromwell
• A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT07196501 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
  NCT05915013 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Connecticut: New Haven
• Assessing the Effectiveness of Digital Wellness Modules on Perceived Quality of Life
  NCT05810259 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · Connecticut: New Haven
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Connecticut: Stamford
• External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
  NCT06788977 · Phase: Not specified · Ages: 18 Years to 44 Years · Sex: Female · Connecticut: Darien
• Imaging Depression in Parkinson's Disease
  NCT06402955 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Connecticut: New Haven
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Cromwell, Farmington
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Cromwell, Farmington
• Open-Label Psilocybin Study in Transdiagnostic Population
  NCT06442423 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
  NCT06713616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Milford, New Haven
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Connecticut: Farmington
• Stress and Pain in People Living With HIV
  NCT06784908 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 68 Years · Sex: All (male and female) · Connecticut: New Haven
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Connecticut: Cromwell
• Study of ALTO-300 in MDD
  NCT05922878 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Connecticut: Norwalk
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Connecticut: Farmington
• Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
  NCT06671977 · Phase: Phase 1 · Ages: 21 Years to 65 Years · Sex: All (male and female) · Connecticut: West Haven
• The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
  NCT07610369 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Connecticut: New Haven
• The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
  NCT05786066 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · Connecticut: West Haven
• The OBSERVE Protocol
  NCT06725277 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Connecticut: Milford, New Haven
• Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder
  NCT06142955 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 40 Years · Sex: All (male and female) · Connecticut: New Haven
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Connecticut: Farmington